Significance of the TPS Cytokeratin Marker in the Postoperative Follow Up of Colorectal Carcinoma Patients

Česká verzia

Authors: K. Rupert; L. Holubec ^*; J. Nosek; K. Houdek; Topolčan O.#; V. Třeška
Authors place of work: Chirurgická klinika FN Plzeň, prof. MUDr. V. Třeška, DrSc. ; Radioterapeutické a onkologické oddělení FN Plzeň, doc. MUDr. J. Fínek, Ph. D. #Oddělení nukleární medicíny, prof. MUDr. O. Topolčan, CSc. ^*
Published in the journal: Rozhl. Chir., 2009, roč. 88, č. 8, s. 428-433.
Category: Monothematic special - Original

Summary

Aim:
Examination of tumour markers conducive to follow up of the patients with colorectal carcinoma.

Material and Methods:
The tumour markers were examined in the population of patients with primarily established and histologically verified colorectal adenocarcinoma.

Results:
The resection therapy resulted in the decrease in post-operative CEA levels. There were no changes in pre- and post-operative CA 19-9 levels; unlike with post-operative TPS levels having been significantly increased, probably due to reparation processes resulting from the surgery. It can be concluded that pre- and post-operative CEA levels are the most suitable markers to check the effect of surgery. With a 95%-specificity for the establishment of recidives, the highest sensitivity was reached with TPS (83%); the sensitivities of the classical tumour markers CEA and CA 19-9 were significantly lower (41% and 25%, respectively). The results should be interpreted with caution due to a small number of relapses regarding a short follow up and rather local-regional character of the recidives.

Conclusion:
However, TPS seems to be a promising marker for the follow up of the patients with colorectal carcinoma. Thus, an ideal combination seems to be that of CEA and TPS.

Key words:
colorectal carcinoma – tumour markers – CEA – CA 19-9 – TPS

Zdroje

1. Becker, H. D., Hohenberg, W., Junginger, T., Schlag, P. M. Chirurgická onkologie. Grada, 2005, p. 3–17, 29–35, 41–46, 457–545.

2. Carpelan-Holmstrom, M., Louhimo, J., Stenman, U. H., Alfthan, H., Jarvinen, H., Haglund, C. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer. Tumour Biol., 2004, Sep-Dec; 25(5-6): 228–234.

3. Duffy, M. J., van Dalen, A., Haglund, C., Hansson, L., Klapdor, R., Lamerz, R., Nilsson, O., Sturgeon, C., Topolcan, O. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur. J. Cancer, 2003 Apr; 39(6):718–727.

4. Fakih, M. G., Padmanabhan, A. CEA monitoring in colorectal cancer. What you should know. Oncology (Williston Park), 2006 May; 20(6): 579–587; discussion 588, 594, 596.

5. Fernandes, L. C., Kim, S. B., Matos, D. Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma. World J. Gastroenterol., 2005 Feb7; 11(5): 645–648.

6. Fernandes, L. C., Kim, S. B., Saad, S. S., Matos, D. Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer. World J. Gastroenterol., 2006 Jun 28; 12(24): 3891–3894.

7. Fletcher, R. H. Successfull colorectal cancer screening starts with primary care. Rev. Gastroenterol. Disord. 2, Suppl. 1, 2002, p. 27–34.

8. Forslund, A., Engaras, B., Lonnroth, C., Lundholm, K. Prediction of postoperative survival by preoperative serum concentrations of anti-p53 compared to CEA, CA 50, CA 242 and conventional blood tests in patients with colorectal carcinoma. Int. J. Oncol., 2002 May; 20(5): 1013–1018.

9. Holubec, L., et al. Kolorektální karcinom – současné možnosti diagnostiky a léčby. Grada, 2004, p. 15–23, 15–18, 103–132.

10. Kim, S. B., Fernandes, L. C., Saad, S. S., Matos, D. Assessment of the value of preoperative sérum levels of CA 242 and CEA in the staging and postoperative survival of colorectal adenocarcinoma patients. Int. J. Biol. Markers, 2003 Jul-Sep; 18(3): 182–187.

11. Körner, H., Söeide, K., Stokkeland, P. J., Soreide, J. A. Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: a receiver operating charakteristic curve analysis. Ann. Surg. Oncol., 2007 Feb; 14(2): 417–423.

12. Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., Bast, R. C. Jr., ASCO ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol., 2006 Nov 20; 24(33): 5313–5327. Epub 2006 Oct23.

13. Louhimo, J., Carpelan-Holmstrom, M., Alfthan, H., Stenman, U. H., Jarvinen, H. J., Haglund, C. Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int. J. Cancer, 2002 Oct 20; 101(6): 545–548.

14. McWilliams, R. R., Erlichman, C. Novel therapeutics in colorectal cancer. Dis. Colon Rectum, 2005 Aug; 48(8): 1632–1650.

15. Nekulová, M., Šimíčková, M., Černoch, M. Charakteristika a využití jednotlivých nádorových markerů. V: Nádorové markery. Boehringer Mannheim Czech, 1996, 15–31.

16. Rejthar, A., Vojtěšek, B. Obecná patologie nádorového růstu. Praha, Grada 2002.

17. Sandelewski, A., Kokocinska, D., Partyka, R., Kocot, J., Starzewski, J., Chanek, I., Jalowiecki, P. Usefulness of evaluation of carcinoembryonic antigen (CEA) and soluble fragments of cytokeratin 18-th (TPS) in postoperative monitoring of patiens with colorectal cancer. Pol. Merkur Lekarski, 2005 Jun; 18(108): 647–650.

18. Schwartz, M. Screening for Colorectal Cancer. In: Topics in Primary Care. University Health Care Services, Chicago, 1998, pp 1–5.

19. von Kleist, S., Hesle, Y., Kananeeh, H. Comparative evaluation of four tumor markers, CA 242, CA 19-9 TPA and CEA in carcinomas of the colon. Anticancer Research. 1996; 16(4B): 2325–2331.